Table 2 Evolution of clinical phenotypes of Behçet’s disease in Japan before correction for the follow-up period
Group A pre 2000 (n = 323) | Group B 2000–2007 (n = 164) | Group C Post 2008 (n = 91) | P | |
|---|---|---|---|---|
Observation time (years) | 11.9 ± 9.3 | 6.3 ± 4.8 | 3.7 ± 2.2 | <0.0001 |
Age at onset | 36.9 ± 11.8 | 35.8 ± 13.1 | 37.6 ± 11.4 | NS |
Gender male, n (%) | 134 (41.5) | 76 (46.3) | 37 (40.7) | 0.80 |
HLA-B51, n (%) | 107 (54.9) | 48 (49.0) | 16 (43.1) | 0.061a |
Complete type, n (%) | 124 (38.4) | 45 (27.4) | 16 (17.6) | <0.0001 |
Oral ulcer, n (%) | 321 (99.4) | 163 (99.4) | 88 (96.7) | 0.065 |
Genital ulcer, n (%) | 246 (76.2) | 116 (70.7) | 55 (60.4) | 0.0033 |
Eye involvement, n (%) | 211 (65.3) | 92 (56.1) | 53 (58.2) | 0.083 |
Skin involvement, n (%) | 293 (90.7) | 145 (88.4) | 75 (82.4) | 0.033 |
Arthritis, n (%) | 166 (51.4) | 87 (53.0) | 48 (52.7) | 0.75 |
Gastrointestinal involvement, n (%) | 37 (11.5) | 20 (12.2) | 14 (16.5) | 0.35 |
CNS involvement, n (%) | 39 (12.1) | 17 (10.4) | 3 (3.3) | 0.023 |
Vascular involvement, n (%) | 26 (8.1) | 17 (10.4) | 3 (3.3) | 0.35 |